Abstract
B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.
| Original language | English |
|---|---|
| Pages (from-to) | 229-231 |
| Number of pages | 3 |
| Journal | Journal of Neuroimmunology |
| Volume | 276 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - Nov 15 2014 |
Fingerprint
Keywords
- B lymphocytes
- CD20
- Neurodegeneration
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology
- Medicine(all)
Cite this
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. / Studer, Valeria; Rossi, Silvia; Motta, Caterina; Buttari, Fabio; Centonze, Diego.
In: Journal of Neuroimmunology, Vol. 276, No. 1-2, 15.11.2014, p. 229-231.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis
AU - Studer, Valeria
AU - Rossi, Silvia
AU - Motta, Caterina
AU - Buttari, Fabio
AU - Centonze, Diego
PY - 2014/11/15
Y1 - 2014/11/15
N2 - B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.
AB - B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.
KW - B lymphocytes
KW - CD20
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=84908546527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908546527&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2014.08.617
DO - 10.1016/j.jneuroim.2014.08.617
M3 - Article
VL - 276
SP - 229
EP - 231
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -